Boston, MANCT07377435Now EnrollingIRB Ready

Multiple Myeloma Clinical Trial in Boston, MA

Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by David Avigan

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access multiple myeloma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple myeloma treatment provided free

Apply for This Boston Location

Check if you qualify for this multiple myeloma clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Multiple Myeloma Study in Boston

This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: * DC/MM fusion vaccine (a type of personalized cancer vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)

Sponsor: David Avigan

Who Can Participate

Inclusion Criteria

Patients must be eligible to receive standard of care CAR T-cell therapy for relapsed or refractory multiple myeloma
Patients must be ≥18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Patients must have 20% or more plasma cells in the bone marrow core or aspirate differential within 30 days prior to enrollment.
Patients must have adequate organ function as defined below:
Total bilirubin ≤ 1.5 x institutional upper limit of normal
AST ≤ 3 x institutional upper limit of normal
ALT ≤ 3 x institutional upper limit of normal
Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal
The effects of DC/MM fusion vaccine on the developing human fetus are unknown. For this reason, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier methods of birth control or abstinence) prior to study enrollment and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of treatment.
Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

Patients receiving other investigational drugs
Patients with Plasma Cell Leukemia
Patients who have known active uncontrolled infections with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)
Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias. Prior to study entry, any ECG abnormality at screening will be documented by the investigator as not medically relevant.
Female patients who are pregnant (positive β-HCG) or breastfeeding.
Prior organ transplant requiring immunosuppressive therapy.
Uncontrolled intercurrent illness including, but not limited to: active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
History of intolerance to CAR-T related drugs or GM-CSF. Inclusion Criteria Prior to Vaccination with DC/MM Fusions:
Resolution of all CAR T- related grade 3-4 toxicities
Successful production of at least 2 vaccines with a minimum of 1 x 106 fusion cells
Absence of disease progression following CAR T-cell therapy
ECOG performance status ≤ 2
Patients must have adequate organ function as defined below:
Total bilirubin ≤ 1.5 x institutional upper limit of normal
AST ≤ 3 x institutional upper limit of normal
ALT ≤ 3 x institutional upper limit of normal
Creatinine within normal limits or Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal
ANC \>1000 in the absence of growth factor support in the prior 7 days
Platelet count \>50K without the need for transfusion in the prior 7 days
No myeloma-directed therapy following administration of CAR T-cells

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07377435) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Boston, MA

If you're searching for multiple myeloma treatment options in Boston, MA, this clinical trial (NCT07377435) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Boston, MA

See all multiple myeloma clinical trials recruiting in Boston — not just this study.

Browse Multiple Myeloma Trials in Boston →

Browse More Trials by Condition

Multiple Myeloma TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA